ANI Pharmaceuticals (ANIP)

Its Rare Disease and Brands segment is a major contributor to revenue and includes products used in areas such as ophthalmology, rheumatology, nephrology, neurology, and pulmonology. Key products include Purified Cortrophin Gel, an adrenocorticotropic hormone therapy used for certain inflammatory and autoimmune conditions, and ophthalmology assets such as ILUVIEN and YUTIQ, fluocinolone acetonide intravitreal implants used in the treatment of specific chronic eye diseases. These products place ANI in markets where physician education, patient access, and specialty distribution are important to commercial success.

The company also maintains a generics business with a portfolio covering a range of therapeutic categories. Generic pharmaceuticals can provide recurring revenue but are often subject to pricing pressure, competition from other manufacturers, supply-chain demands, and regulatory oversight. ANI’s manufacturing and development capabilities support both internal products and selected external opportunities.

ANI Pharmaceuticals earns the majority of its revenue in the United States, with additional exposure to other markets. Its investment case is tied to execution in rare disease commercialization, lifecycle management of branded assets, and the stability of its generics portfolio. The company stands out for blending specialty pharmaceutical products with a manufacturing-backed generics platform.